Kairos Pharma ENV-105 Shows Favorable Safety in Lung Cancer Trial
Kairos Pharma reports favorable interim safety for ENV-105 in combination with osimertinib for resistant EGFR-mutated NSCLC. No Grade 3+ adverse events seen in 13 patients.
This news matters because it offers hope for patients with EGFR-mutated non-small cell lung cancer who have developed resistance to osimertinib, the current standard of care. If ENV-105 proves effective, it could significantly extend the duration of benefit from osimertinib, providing an additional treatment option and potentially improving survival outcomes in a patient population with limited alternatives.
